A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma

Leiby, Benjamin E.; Hegarty, Sarah; Myers, Jonathan S.; Katz, L. Jay; Haller, Julia A.; Waisbourd, Michael; Burns, Christine; Divers, Meskerem; Molineaux, Jeanne; Henderer, Jeffrey; Brodowski, Charles; Hark, Lisa A

doi:10.5888/pcd18.200567

Cited by 15 publications

(25 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assistance from patient navigators has led to improved health outcomes in fields such as cardiology [ 55 ] and women’s health [ 56 ]. In ophthalmology, a community-based study found that use of a patient navigator improved appointment follow-up rates after screening for glaucoma [ 57 ]. Similarly, a social worker intervention in eye clinic settings effectively addressed barriers for most patients and reduced patient distress [ 58 , 59 ].…”

Section: How Ophthalmologists Can Take Action To Address Social Needsmentioning

confidence: 99%

Addressing Social Determinants of Vision Health

Williams

Sahel

2022

Ophthalmol Ther

View full text Add to dashboard Cite

Social determinants of health encompass the quality of an individual’s social and physical environment and its effect on health outcomes. Disparities in these social and environmental factors have a significant role in vision health disparities and inequity in eye care. In this review, we discuss how disparities in visual impairment and eye care utilization are affected by each of the five core domains of social determinants of health, namely economic stability (income, employment, and food security), education (education level and health literacy), health care access (insurance and medical costs), neighborhood environment (housing conditions, home ownership, pollution, and crime), and social context (race and racism). Moreover, we describe a framework by which ophthalmologists can take action to address social determinants of vision health. These actionable strategies are guided by recommendations from the National Academies of Sciences, Engineering, and Medicine and have five complementary components to address social needs: awareness (screening for social needs), assistance (connecting patients with social care resources), adjustment (altering clinical care in recognition of social needs), alignment (understanding social assets and collaborating with community organizations), and advocacy (promoting policies to address social needs). Addressing social determinants of health is complex but achievable through collaborative strategies. Ophthalmologists have an important leadership role in addressing eye care disparities by taking action on underlying social determinants of vision health.

show abstract

Section: How Ophthalmologists Can Take Action To Address Social Needsmentioning

confidence: 99%

Addressing Social Determinants of Vision Health

Williams

Sahel

2022

Ophthalmol Ther

View full text Add to dashboard Cite

show abstract

“…While real-world studies, such as the VISIONARY study, provide an important opportunity to examine the treatment outcomes achieved in routine clinical practice, this type of study is associated with a number of limitations. Patients were able to leave the study without providing a reason, and attendance at follow-up appointments also represents a major challenge for ophthalmologists in clinical practice [ 42 ]. Patients were only mandated to attend study visits at baseline and Month 6, meaning that fewer patients attended interim visits at Weeks 4 and 12, and this is reflected in the data reported at these timepoints.…”

Section: Discussionmentioning

confidence: 99%

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Oddone

Fassari

Faschinger³

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Introduction The VISIONARY study demonstrated statistically significant intraocular pressure (IOP) reductions with the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (PF tafluprost/timolol FC) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients, sub-optimally controlled with topical prostaglandin analogue (PGA) or beta-blocker monotherapy. Current subanalyses have examined these data according to the baseline monotherapy. Methods A European, prospective, observational study included adults (aged ≥ 18 years) with OAG or OHT, who were switched to the PF tafluprost/timolol FC from PGA or beta-blocker monotherapy. Treatment outcomes were reported according to prior monotherapy subgroup: beta-blocker, preserved latanoprost, PF-latanoprost, bimatoprost, tafluprost, and travoprost. Endpoints included the mean change from baseline regarding IOP, conjunctival hyperemia, and corneal fluorescein staining (CFS) at Week 4 and Week 12, and at Month 6. Results The subanalysis included 577 patients. All prior monotherapy subgroups demonstrated statistically significant IOP reductions from baseline at Week 4, that were maintained through Month 6 ( p < 0.001). Mean (SD) IOP change at Month 6 was 6.6 (4.16), 6.3 (4.39), 5.6 (3.67), 4.9 (2.97), 4.6 (4.39), and 4.7 (3.64) mmHg for prior beta-blocker, preserved latanoprost, PF-latanoprost, tafluprost, bimatoprost, and travoprost subgroups, respectively. The largest IOP change was observed in the preserved latanoprost subgroup for each of the ≥ 20%, ≥ 25%, ≥ 30%, and ≥ 35% IOP reduction categories at Month 6, demonstrating respective reductions of 8.06, 9.20, 10.64, and 11.55 mmHg. CFS was significantly reduced at Month 6 in the prior bimatoprost subgroup ( p = 0.0013). Conjunctival hyperemia severity was significantly reduced at each study visit for prior preserved latanoprost users ( p < 0.001). Conclusion PF tafluprost/timolol FC therapy provided statistically and clinically significant IOP reductions from Week 4 over the total 6-month period, in patients with OAG/OHT, regardless of the type of prior PGA or beta-blocker monotherapy used. Conjunctival hyperemia severity and CFS decreased significantly in prior bimatoprost and preserved latanoprost users, respectively. Clinical Study Number European Union electronic Register of Post-Authorization Studies (EU PAS) register number: EUPAS22204. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02166-6.

show abstract

“…According to the Lancet Global Health Commission on Global Eye Health, women, rural populations, and racial/ethnic minority groups are more likely to have vision impairment, a pervasive inequality that needs to be addressed ( 40 ). This PCD collection on advancing health equity and reducing health disparities concludes with a research study by Leiby et al investigating the effectiveness of an enhanced intervention among people with glaucoma: using patient navigators and social workers to improve patient adherence to follow-up eye care in community settings ( 20 ). The study compared the intervention group with a group of patients in usual care.…”

mentioning

confidence: 99%

“…A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma ( 20 )…”

mentioning

confidence: 99%

Advancing Health Equity, Eliminating Health Disparities, and Improving Population Health

Jack

2021

Prev. Chronic Dis.

View full text Add to dashboard Cite

A Randomized Trial to Improve Adherence to Follow-up Eye Examinations Among People With Glaucoma

Cited by 15 publications

References 25 publications

Addressing Social Determinants of Vision Health

Addressing Social Determinants of Vision Health

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment

Advancing Health Equity, Eliminating Health Disparities, and Improving Population Health

Contact Info

Product

Resources

About